Eloxx Pharmaceuticals posts Q3 2026 loss, doses first Alport patients and secures ADPKD IND

Eloxx Pharmaceuticals reported a net loss of $5.54 million for the quarter ended September 30, 2026. The company dosed the first two patients in its Phase 2b EXACT study for nonsense‑mutation Alport syndrome and received IND clearance for a Phase 2 EXPRESS study in ADPKD. Cash and cash equivalents were reported at roughly $56 million, which the company says will fund operations into 2028, and it added T.R. Srinivas, M.D. as senior vice‑president and chief medical officer.

The cash runway into 2028 gives Eloxx operational continuity despite the widened loss (the press release states the cash will last into 2028). Progress on the Alport and ADPKD trials could drive future revenue if the studies succeed, as noted in the business update.

  • 1Net loss for Q3 2026 was $5.54 million.
  • 2Cash and cash equivalents were $56.3 million as of September 30, 2026.
  • 3R&D expenses were $4.0 million for the quarter.
  • 4First two patients were dosed in the Phase 2b EXACT Alport study in September 2026.
  • 5Topline data from the 16‑week placebo‑controlled portion of the Alport study are expected in mid‑2027.
  • 6T.R. Srinivas, M.D. was appointed senior vice‑president and chief medical officer.

Sources